CDC: Typhoid Infections Often Resist Ciprofloxacin

A CDC cross-sectional study finds enteric fever in US travelers is likely resistant to ciprofloxacin, with multidrug resistance rising among certain travel routes.

Updated on Nov. 12, 2026 in Diseases — General

Amber culture plates and glass test tubes on a steel laboratory bench, with a brass microscope softly blurred behind them in cool daylight.
The CDC reports that typhoid infections in travelers returning to the United States are increasingly resistant to ciprofloxacin, with some cases also resisting ceftriaxone. AI Illustration. Upload story photo >

Live Poll

Did you get a typhoid vaccine before your last trip abroad?

CDC investigators found that enteric fever infections in travelers returning to the United States are likely resistant to ciprofloxacin, and some cases also resist ceftriaxone. The cross-sectional study, which updates prior CDC data on antimicrobial resistance, advises treatment guided by susceptibility testing whenever possible.

Why it matters

Fluoroquinolone-nonsusceptible Typhi isolates rose from 12.0% in 1999 to 75.1% in 2023, narrowing the antibiotic options available to clinicians treating travelers. Because resistance can evolve quickly, ongoing surveillance is needed to detect emerging resistance and guide treatment decisions.

Fluoroquinolone-nonsusceptible Typhi isolates climbed from 12.0% in 1999 to 75.1% in 2023, and 8.7% of isolates were multidrug resistant in 2016-2020. The odds of multidrug-resistant Typhi were 37.84 times higher among travelers returning from the Indian subcontinent than from other destinations.

The players

Centers for Disease Control and Prevention (CDC)

The CDC is the United States federal public health agency that conducts disease surveillance and issues treatment and travel guidance.

The details

Investigators analyzed antimicrobial resistance in enteric fever cases in the United States to update prior CDC data. Typhoid fever spreads via the fecal-oral route, usually through contaminated water or food, and travelers to high-risk destinations are advised to be vaccinated before departure.

Timeline

  1. 1999: Fluoroquinolone-nonsusceptible Typhi baseline measured at 12.0%.

  2. 2007: Paratyphi fluoroquinolone-nonsusceptibility peaked and remained high afterward.

  3. 2016: XDR Typhi strain first identified among travelers returning from Pakistan.

  4. 2016-2020: 8.7% of Typhi isolates were multidrug resistant.

  5. 2023: 75.1% of Typhi isolates were fluoroquinolone-nonsusceptible.

Health Landscape

This update extends the CDC's earlier antimicrobial resistance tracking for enteric fever, showing fluoroquinolone nonsusceptibility in Typhi rising from 12.0% in 1999 to 75.1% in 2023. The trend points to a steadily shrinking set of effective oral antibiotics for travel-associated typhoid and paratyphoid infections.

Travelers to South Asia, Pakistan, and other high-risk destinations should get typhoid vaccinated before departure and ask their clinicians about susceptibility testing if they become ill. Because ciprofloxacin may not work against these infections, treatment choices should be guided by lab results rather than assumed.

The takeaway

Travelers returning from high-risk regions should seek testing if they develop fever, because standard antibiotics may fail and susceptibility-guided treatment is safer.

Further reading

For broader context on infectious disease trends, explore Diseases — General coverage.

Source note: This article includes information reported by Contagionlive.

Live Poll

Did you get a typhoid vaccine before your last trip abroad?